BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31319972)

  • 1. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Gibson AJW; Li H; D'Silva A; Elegbede AA; Tudor RA; Otsuka S; Bebb DG; Cheung WY
    Lung Cancer; 2019 Aug; 134():141-146. PubMed ID: 31319972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
    Wallington M; Saxon EB; Bomb M; Smittenaar R; Wickenden M; McPhail S; Rashbass J; Chao D; Dewar J; Talbot D; Peake M; Perren T; Wilson C; Dodwell D
    Lancet Oncol; 2016 Sep; 17(9):1203-16. PubMed ID: 27599138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
    Oselin K; Pisarev H; Ilau K; Kiivet RA
    BMC Cancer; 2021 Mar; 21(1):274. PubMed ID: 33722202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty-day mortality after systemic anticancer treatment as a real-world, quality-of-care indicator: the Northland experience.
    Ang E; Newton LV
    Intern Med J; 2018 Apr; 48(4):403-408. PubMed ID: 28872748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer chemotherapy treatment outcomes and ethnicity: a twenty-year single-centre patterns of care study.
    Nguyen H; Keenan R; Kennedy I; Lao C; Lawrenson R
    N Z Med J; 2023 Nov; 136(1585):24-34. PubMed ID: 37956355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
    Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Manley Daumont M; Penrod JR; O'Donnell JC; Hall G
    BMJ Open; 2021 May; 11(5):e043442. PubMed ID: 33941627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Anti-Cancer Therapy Use in Palliative Care Outpatients With Advanced Cancer.
    Wadhwa D; Hausner D; Popovic G; Pope A; Swami N; Maganti M; Zimmermann C
    J Palliat Care; 2021 Apr; 36(2):78-86. PubMed ID: 33241732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
    Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
    Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
    Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
    Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre.
    Khoja L; McGurk A; O'Hara C; Chow S; Hasan J
    Eur J Cancer; 2015 Jan; 51(2):233-40. PubMed ID: 25500146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.
    Beaudet MÉ; Lacasse Y; Labbé C
    Curr Oncol; 2022 Feb; 29(3):1316-1325. PubMed ID: 35323312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka S; Bebb DG; Cheung WY
    Am J Clin Oncol; 2019 Jan; 42(1):75-81. PubMed ID: 30211724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
    Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
    JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
    Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
    Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.
    Wei S; Tian J; Song X; Wu B; Liu L
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):145-155. PubMed ID: 28980067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Vinod SK; Chandra A; Berthelsen A; Descallar J
    Lung Cancer; 2017 Oct; 112():16-24. PubMed ID: 29191589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset.
    Pilleron S; Morris EJA; Dodwell D; Franks KN
    J Geriatr Oncol; 2023 Sep; 14(7):101581. PubMed ID: 37421786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.